Comparing 4 approaches for castration-resistant prostatic neoplasms

Exclusion

• −HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• −Concurrent active HBV or HCV infections.
• −The main exclusion criteriaExclusion criteriaThe things that would prevent someone from taking part.Read more → include but are not limited to the following:
• −History of pituitary dysfunction.
• −Poorly controlled diabetes mellitus.
• −Active or unstable cardio/cerebro-vascular disease, including thromboembolic events and history of stroke or transient ischemic attack within 6 months before the first dose of study intervention, history of myocardial infarction within 6 months before the first dose of study intervention, New York Heart Association Class III or IV cardiac disease or congestive heart failure, coronary heart disease that is symptomatic, or unstable angina
• −History or family history of long corrected QT interval (QTc) syndrome.
• −Myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or features suggestive of MDS/AML.
• −History or current condition of adrenal insufficiency.
• −History of (noninfectious) pneumonitis requiring steroids, or current pneumonitis.
• −Received a whole blood transfusion in the last 120 days before randomizationRandomisedWhich group you go into is decided by chance, not by you or your doctor.Read more → (packed red blood cells and platelet transfusions are acceptable if not given within 28 days before randomization).
• −Received prior systemic anticancer therapy including investigational agents within 4 weeks before randomization.
• −Received a live or live-attenuated vaccine within 30 days before the first does of study intervention. Administration of killed vaccines is allowed.
• −Diagnosis of immunodeficiency, or is receiving chronic systemic steroid therapy, or any other form of immunosuppressive therapy, within 7 days prior to the first dose of study intervention.
• −Known additional malignancy that is progressing or has required active treatment within the past 3 years.
• −Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
• −Active autoimmune disease that has required systemic treatment in the past 2 years.
• −Active infection requiring systemic therapy.
• −Undergone major surgery, including local prostate intervention (except prostate biopsy) within 28 days before randomization, and has not recovered from the toxicities and/or complications.
• −Is on an unstable dose of thyroid hormone therapy within 6 months prior to first dose of study intervention.
• −Received prior radiotherapy within 2 weeks of start of study intervention or radiation-related toxicities, requiring corticosteroids.